Changes in psychological states of caregivers of patients with moderate or severe Alzheimer’s disease following Memantine therapy

Mingyi Ma, Jingtao Wang, Boai Zhang

First Department of Neurology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China. jtclay2008@126.com

Abstract: To assess the psychological states of caregiver of patients with moderate or severe Alzheimer’s disease and to explore the effects of memantine therapy for patients on them, 40 patients with moderate or severe Alzheimer’s disease and their caregivers were recruited. Patients were treated for 6 months with open-label memantine. Caregivers were assessed at baseline and month 6. Their psychological states were assessed by Symptom Checklist 90, Self-Rating Anxiety Scale (SAS) and Self-rating depression scale(SDS). Difference of their psychological states between different time points and normal Chinese scale were analysed by T-test. Results showes that there are significant difference in depression, anxiety, hostility, paranoia and total SCL-90 scale between baseline and month 6 (all p<0.05). When compared to normal SCL-90 scale, there are significant difference in all of items except compulsion, phobophobia and psychosis at baseline where no significant difference in all of items between month 6 and normal scale. There are significant difference in SDS and SAS scale of caregivers between baseline, month 6 and Chinese normal scale. In a word, caregivers of patients with moderate to severe Alzheimer’s disease may have worse psychological states than normal population and memantine therapy for AD patients maybe alleviate these problems.

Key Words Alzheimer’s disease; caregiver; psychological states; memantine

1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive and functional impairment, and behavioural and psychological symptoms of dementia (BPSD). While BPSD are highly prevalent at all stages of dementia, they are particularly common in severe dementia, with 90% of individuals with severe disease exhibiting one behaviour and 50% having at least four. AD caregivers are often subject to enormous stressors and are at high risk for depression with nearly half of caregivers in some studies meeting formal diagnostic criteria for depression. Caregivers also show increased utilization of health services and psychotropic medications, and one study reported that caregivers who reported distress were 63% more likely than noncaregivers to die within 4 years. Thus, adverse effects of care giving seem to be especially pronounced among dementia caregivers, even after controlling for intensity of care giving involvement.

The current study examined the effectiveness of memantine on psychological problems of caregivers of patients with moderate or severe Alzheimer’s disease. The objective is to confirm the effectiveness of memantine in the real world setting and to determine whether treatment with memantine would be associated with decreases in nursing burden, caregiver distress and use of as required medications.

2. Subjects and methods
All AD patients come from consecutive AD patients of neurological outpatient clinics and ward from September 2010 to September 2011. Each subject underwent a comprehensive diagnostic screening assessment including physical and psychiatric examinations, as well as a review of his/her medical history. All patients were residing in Zhengzhou, met NINCDS-ADRDA criteria for probable Alzheimer’s disease, had moderate to severe AD as demonstrated by a score of 0–15 on the Mini-Mental State Examination (MMSE). Their caregivers who interested in and agreed to the study were recruited.

Patients meeting entrance criteria were treated for 6 months with open-label memantine. The memantine (Ebixa) used in this study was provided by Lundbeck Denmark, Inc.. The memantine dose was started at 5mg daily for 1 week and titrated by 5mg/week to 10 mg twice daily for the following weeks. Caregivers were assessed two times: at baseline and month 6. Psychological states were assessed used: ①Symptom Checklist 90 (SCL-90) which assesses 10 behaviours occurring in caregivers: somatization, compulsion, interpersonal
relation, depression, anxiety, hostility, phobophobia, paranoia and psychosis; ② Self-Rating Anxiety Scale (SAS)\[^5\]; ③ Self-rating depression scale (SDS)\[^5\].

All datas were showed as mean±SD and difference between baseline, month 6 and Chinese normal scale were analysed by T-test with SPSS 14.0 software. The p value less than 0.05 was considered to be significantly different.

### 3. Results

40 AD patients and their caregivers who met the including criteria were enrolled. Table 1 summarized their sociodemographic characteristics. The mean age of patients is 73.30±7.54 years and of caregivers is 61.55±5.77 years. Percentage of male in patients is 40.25% whereas in caregivers is 55.00%. For education level, most of patients are less-educated and most of caregivers are moderate-educated. With regard to relation with patients, 62.5% of caregivers is spouse of patients and 20% is children of patients.

Table 2 shows the difference in caregivers’ SCL-90 scales between baseline and month 6, normal scale. There are significant difference in depression, anxiety, hostility, paranoia and total SCL-90 scale between baseline and month 6. When compared to Chinese normal scale, there are significant difference in all of items except compulsion, phobophobia and psychosis at baseline. There is no significant difference in all of items between month 6 and normal scale.

Table 3 shows the of SAS, SDS scale of caregivers between baseline, month 6 and Chinese normal scale. There are significant difference in depression, anxiety scale of caregivers between baseline, month 6 and Chinese normal scale.
Table3. Comparison of SAS, SDS scale of caregivers between baseline, month 6 and Chinese normal scale

<table>
<thead>
<tr>
<th>Items</th>
<th>AD caregivers(n=40)</th>
<th>normal model(n=1388)</th>
<th>t1</th>
<th>t2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>baseline</td>
<td>month 6</td>
<td>t1</td>
<td>t2</td>
</tr>
<tr>
<td>SAS</td>
<td>31.57±5.62</td>
<td>29.12±3.03</td>
<td>29.78±0.46</td>
<td>5.30^a</td>
</tr>
<tr>
<td>SDS</td>
<td>36.30±6.48</td>
<td>34.14±5.67</td>
<td>33.46±8.55</td>
<td>4.03^a</td>
</tr>
</tbody>
</table>

Note: t1—baseline VS month 6; t2—bseline VS normal model. a—p<0.01

4. Discussion

The current study indicated that caregivers of patients with moderate or severe Alzheimer’s disease had worse psychological states than normal population. These problems are: depression, anxiety, hostility and paranoia. Psychiatric and behavioral symptoms occur in the majority of patients with AD over the course of the illness50–52 especially in moderate or severe states, with symptoms of depression among 20%– 50%; patients with AD; agitated or aggressive behaviors appearing in 70%; and delusions or hallucinations in as many as 30%–50%[6].

In fact, depression and psychosis are included as descriptors in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria for AD. One recent study have shown that the direct influence of patients’ cognition on caregiver burden is limited and rather mediated by other disease indicators. Both ADL-abilities and behavioral disturbances are important predictors of perceived caregiver burden, where the latter has the strongest effect[7]. Another study[8] indicated that more severe psychiatric and behavioral problems, along with decreased quality of life were all significantly associated with higher levels of burden, and depression among caregivers. The most frequently used pharmacological treatment for Psychiatric and behavioral symptoms is antipsychotics, particularly atypical antipsychotics. Although their use has been supported by evidence from randomized controlled trial (RCT) data, there remain concerns about potential side effects, such as cerebrovascular adverse events, extrapyramidal side effects and metabolic effects[9].

The results of this study showed that memantine can alleviate the worse psychological states of caregivers of patients with moderate or severe AD. The best-studied treatment for moderate to severe AD is the non-competitive NMDA receptor antagonist memantine, which has been shown to be efficacious in RCTs. With regard to its effect on BPSD, a pooled analysis of the effect of memantine treatment in three large 6-month RCTs in moderate to severe AD patients with agitation and aggression or psychosis showed an advantage for memantine over placebo on the Neuropsychiatric Inventory (NPI) agitation/aggression subscale at week 12 and weeks 24/28[10]. The decreased agitated and aggressive behaviour in institutionalized patients with moderate to severe AD following treatment with memantine was accompanied by improvements in nursing burden and decreased psychotropic use[11].

In a conclusion, this study indicated that caregivers of patients with moderate to severe Alzheimer’s disease may have worse psychological states than normal population and memantine therapy for AD patients maybe alleviate these problems. This conclusion need much more studies to verificated.

Corresponding Author:
Dr Jingtao Wang
First Department of Neurology
First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan 450052, China
jtclay2008@126.com

References
7. Niklas B, Per B, Daniel E.et al. Relative importance of patient disease indicators on informal care and caregiver burden in